AL amyloidosis can feel overwhelming — but understanding it doesn’t have to be. Join us to learn how the disease is diagnosed, what available treatment options and how to spot signs that the disease may be returning or changing. We’ll also explore what’s next in care, including promising new therapies and clinical trials. The webinar will conclude with a Q&A session.
Original Presentation Date:
June 26, 2026
0:00 — Welcome
3:40 — Introduction
5:22 — What is amyloidosis?
12:17 — How can AL (light chain) amyloidosis affect the body?
13:27 — What is AL (light chain) amyloidosis?
16:18 — How is AL (light chain) amyloidosis treated?
20:23 — ANDROMEDA: CyBorD (+/- daratumamab)
31:13 — What is relapsing AL (light chain) amyloidosis?
34:20 — What’s the role for stem cell transplant in 2026?
40:03 — How is relapsing AL (light chain) amyloidosis treated?
42:23 — What’s the future of AL (light chain) amyloidosis treatment?
49:45 — Summary
50:49 — Q&A Session
51:00 — How is t(11;14) identified?
53:02 — What is an m-spike?
53:58 — What are the pros/cons of continuing daratumamab after the 2 year protocol?
55:16 — How many people have relapsing AL (light chain) amyloidosis?
56:33 — Do AL (light chain) amyloidosis patients need a cardiac workup?
57:29 — At what point would you recommend a stem cell transplant?
59:28 — Should AL (light chain) amyloidosis patients have a multidisciplinary care team?
1:00:40 — What’s the percentage of kappa v lambda AL (light chain) amyloidosis patients?
1:01:08 — Conclusion
Contact ARC:
Call +1 (617) 467-5170
Email ARC at support@arci.org
